// App-Quantinova.ai

7014 : Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.

Researchers

Presenter

  • Nicholas James Short

Principal Investigators

  • Hagop M. Kantarjian

  • Susan Mary O'Brien

  • Farhad Ravandi

  • Deborah A. Thomas

  • Guillermo Garcia-Manero

  • Naval Guastad Daver

  • Gautam Borthakur

  • Nitin Jain

  • Marina Konopleva

  • Koji Sasaki

  • Naveen Pemmaraju

  • Yesid Alvarado

  • Jovitta Jacob

  • Rebecca Garris

  • Philip A. Thompson

  • Jorge E. Cortes

  • Elias Jabbour

Medical Centers

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • University of California, Irvine, Fullerton, CA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Rituximab

  • ara-c

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT01371630

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved